Ipsen Olivia Brown appoints as the head of the executive vice president, the head of global neurotoxins

Item content

Paris, France, March 12^th2025 – Ipsen (EURONEXT: IPN; ADR: IPN: IPNE), a global qualified care-based company, Today Olivia Brown, EVP, April 1, April 1, announced that Olivia Brown is appointed today^f2025. He will serve the IMSEN’s executive (ELT) and serve Direct CEO David Loew. In this newly generated role, it will take the global neurotoxin franchise, which controls strategy and implementation of strategy and implementation of both therapeutic and aesthetic tips.

Item content

Item content

Item content

Over the past 30 years, the Neurotoxin market set up as one of the leading players of Neuroscales, successful governance, clinical development and growth, significant production, cinning and growth, established itself as a basis of growth, clinical development and growth.

“We are pleased to welcome Olivia to the executive management of Ipsen. He will be instrumental by the global strategy and commercial experience in neurotoxin, with a global strategy and commercial experience. After that We both grow and keep our innovations in neurotoxins in the therapeutic and aesthetic space “ said David Loew, CEO, Ipsen. “A solid portfolio of products and attractive pipeline including potentially uninterrupted innovation recombinant Long-caseActing
The Neuro-Toxine (LANT) program is the most suitable time to create an integrated franchise. Long actor Neurotoxin is designed to connect to receptors used by Bont B and convey the active light chain of work in the stall, pre-researches and compare less tissue spreads and less tissue spreads and less tissue distribution. We believe that the lion has the EU potential ability To give better results for patients with a period of action that causes potential reduction in injection and developed tolerance. “

Item content

Item content

Olivia was in Novartis, which recently led to a new therapeutic area with global leadership experience, airmeal and medical aesthetics, market expansion and product. Earlier, he held a high leadership position in Merz Aesthetics and Galderma, where the global neurotoxin market has played a key role in expanding the market.

“I am pleased to join Ipsen at such an important time for his neurotoxin. IPSen Innovation I am looking forward to working with the team to build this success and increase the success of this dynamic market” said Olivia Brown.

This destination continues to lead to neurotoxin innovation, global expansion and aesthetic signs in both therapeutic and aesthetic signs.

* Botulinum toxin Type B (Bont-B)
** Botulinum toxin type A (Bont

About Ipsen
We are a global biofarmaceutical company aimed at bring transformative medications to patients in three therapeutic areas: oncology, rare disease and neurology. Along with our foreign innovations, our pipeline allows us to bring medications in more than 40 countries in the United States, France and Britain in France and Britain, and our partnership in France and Britain. Ipsen is listed in Paris (EUROXT: IPN) and the United States with the American Deposit Admission Program (ADR: IPSey). For more information, visit Ipsen.com.

Item content

Ipsen Contact

Investors

• Alina Levchuk | + 41 79 572 8712 | alina.levchuk@ipsen.com
• Nikolas Bogler | + 33 6 52 19 98 92 | nicolas.bogler@ipsen.com
  

Media

• Sally Bain | + 1 857 320 0517 | sally.ben@ipsen.com
• Anne LiTas | + 33 7 67 34 72 96 | Anne.lionon.ext@ipsen.com

Refusal and / or forward-looking phrases
The forward-looking phrases, goals and goals are based on the Ispsen’s management strategy, current landscapes and assumptions. It will distinguish between such expressions, known and unknown risks and unknown risks and unknown risks and uncertainties that may lead to actual results, performance or incidents. All the above risks can achieve their future ability to achieve financial goals with acceptable macroeconomic conditions based on the existing information today. The use of the words ‘believes’, ‘waiting’ and ‘waiting’ and similar expressions are planned to identify the following statements, including those events, including regulatory documents and determination. Moreover, the goals described in this document are made without external growth assumptions and potential future purchases, it can change these parameters. These goals are based on information and assumptions considered acceptable by Ipsen. These goals depend on the possibility of happening in the future or the facts and are not only over historical data. True results, given the occurrence of certain risks and uncertainties of these goals, especially in the early stage or in the market for a prospective drug or reaching the market, the reasons for the reasons for the reasons, may be faces or competition. In addition, the process of research and development covers several stages each of which will be forced to leave a drug that is not able to achieve the goals of the Ismons and significant amounts. Therefore, the favorable results obtained during prinical tests will not be determined to be approved during clinical trials or demonstrate the safe and effective nature of the concerned medications of clinical tests. A drug cannot be a guarantee that will receive the necessary adjustment approval or that the drug will be commercially successful. Assumptions are incorrect assumptions emerge, if the incorrect or uncertainties emerge, the actual results may differ in material ways. Includes other risks and uncertainties, but are not limited to general industrial conditions and competition; General economic factors, including interest rate and exchange rate volatility; Regulation of the pharmaceutical industry and the impact of health legislation; Global trends against health care costs; Technological developments of competitors, new medicine and patent; To receive adjustments, including difficulties inherent in the development of new medical development; The ability to accurately predict the future market conditions of Ipsen; the difficulties or delays in production; financial instability of international economies and sovereign risks; Dependence on the effectiveness of other protection for the patents and innovative drugs of IPSen; and the court or adjustment actions, including the court. Ipsen also depends on third parties to develop and market part of the medicines that produce a large royalty; These partners may behave in the way that can damage the activities and financial results of Ishmon. Could not be sure that the Ipsen partners will fulfill their obligations. It will not be able to obtain any benefits from these agreements. Default of any of the Ipsen partners can get lower income than expected. In such cases, Ipsen may have a negative impact on the financial position or performance. Ipsen denies any obligations or assessments of events, conditions, assumptions or any expressions, assumptions, assumptions, assumptions, or estimates, or assessments of any expressions, objects or assessments, or assessments of any expressions, objects or evaluations, if applicable. The work of the Ipsen is subject to the risk factors shown in the recording documents provided by French Autorité des Marchés financiers. The above risks and uncertainties are not complete and are recommended to contact the last universal registration document available on the Ipsen.com.

Carpet-maker

• PR_ELT announcement_13032025

Item content